Drug intelligence / Profile preview

BCC-903

Development stage: Preclinical
Lead developer: Aquavit Pharmaceuticals
Modality: Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
Administration: Intradermal

Overview

**BCC-903**, also identified by Aquavit Pharmaceuticals as **ACK-122/BCC-903**, is an investigational oncology combination-product program for **basal cell carcinoma** and **actinic keratosis**. Aquavit has publicly identified the program in its development portfolio and stated that development was initiated, but it has not publicly disclosed the active ingredients, dosage form, route of administration, molecular targets, mechanism of action, clinical phase, or manufacturing details. ([aquavitpharma.com](https://aquavitpharma.com/companies/aquavit-pharmaceuticals))

Beyond the preview

Go deeper on BCC-903.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BCC-903.

Explore the full profile